Safety and feasibility of platelet rich fibrin matrix injections for treatment of common urologic conditions

다국어 초록 (Multilingual Abstract)

Purpose: Autologous platelet rich plasma (PRP) is used increasingly in a variety of settings. PRP injections have been used for decades to improve angiogenesis and wound healing. They have also been offered commercially in urology with little to no data on safety or efficacy. PRP could theoretically improve multiple urologic conditions, such as erectile dysfunction (ED), Peyronie's disease (PD), and stress urinary incontinence (SUI). A concern with PRP, however, is early washout, a situation potentially avoided by conversion to platelet rich fibrin matrix (PRFM). Before clinical trials can be performed, safety analysis is desirable. We reviewed an initial series of patients receiving PRFM for urologic pathology to assess safety and feasibility.
Materials and Methods: Data were reviewed for patients treated with PRFM at our center from November 2012 to July 2017. Patients were observed immediately post-injection and at follow-up for complications and tolerability. Where applicable, International Index of Erectile Function (IIEF-5) scores were reviewed before and after injections for ED and/or PD. Pad use data was collected pre/post injection for SUI.
Results: Seventeen patients were identified, with a mean receipt of 2.1 injections per patient. Post-procedural minor adverse events were seen in 3 men, consisting of mild pain at injection site and mild penile bruising. No patients experienced complications at follow-up. No decline was observed in men completing pre/post IIEF-5 evaluations.
Conclusions: PRFM appears to be a safe and feasible treatment modality in patients with urologic disease. Further placebo-controlled trials are warranted.

참고문헌 (Reference)

1 Jiritano F, "Ventricular assist device driveline infection: treatment with platelet-rich plasma" 96 : e37-e38, 2013

2 Vlachopoulos C, "Unfavourable endothelial and inflammatory state in erectile dysfunction patients with or without coronary artery disease" 27 : 2640-2648, 2006

3 Wu CC, "The neuroprotective effect of platelet-rich plasma on erectile function in bilateral cavernous nerve injury rat model" 9 : 2838-2848, 2012

4 Levine LA, "Standard operating procedures for Peyronie's disease" 10 : 230-244, 2013

5 Werner S, "Regulation of wound healing by growth factors and cytokines" 83 : 835-870, 2003

6 Randelli P, "Regenerative medicine in rotator cuff injuries" 2014 : 129515-, 2014

7 Maher CF, "Pubovaginal sling versus transurethral Macroplastique for stress urinary incontinence and intrinsic sphincter deficiency: a prospective randomised controlled trial" 112 : 797-801, 2005

8 Zhou B, "Protection of colonic anastomosis with platelet-rich plasma gel in the open abdomen" 45 : 864-868, 2014

9 Nurden AT, "Platelets and wound healing" 13 : 3532-3548, 2008

10 Andia I, "Platelet-rich plasma for managing pain and inflammation in osteoarthritis" 9 : 721-730, 2013

11 Schiavone G, "Platelet-rich plasma for androgenetic alopecia: a pilot study" 40 : 1010-1019, 2014

12 Galliera E, "Platelet rich plasma therapy: inflammatory molecules involved in tissue healing" 26 (26): 35S-42S, 2012

13 Sampson S, "Platelet rich plasma injection grafts for musculoskeletal injuries: a review" 1 : 165-174, 2008

14 Gigante A, "Platelet rich fibrin matrix effects on skeletal muscle lesions: an experimental study" 26 : 475-484, 2012

15 Kushida S, "Platelet and growth factor concentrations in activated platelet-rich plasma: a comparison of seven commercial separation systems" 17 : 186-192, 2014

16 Li J, "Phosphodiesterase type 5 inhibitors for the treatment of post-nerve sparing radical prostatectomy erectile dysfunction in men" 4 : 5801-, 2014

17 Greenfield JM, "Peyronie's disease: etiology, epidemiology and medical treatment" 32 : 469-478, 2005

18 Wu YN, "Optimization of platelet-rich plasma and its effects on the recovery of erectile function after bilateral cavernous nerve injury in a rat model" 10 : E294-E304, 2016

19 Derby CA, "Measurement of erectile dysfunction in population-based studies: the use of a single question self-assessment in the Massachusetts Male Aging Study" 12 : 197-204, 2000

20 Davis NF, "Injectable biomaterials for the treatment of stress urinary incontinence: their potential and pitfalls as urethral bulking agents" 24 : 913-919, 2013

21 Feldman HA, "Construction of a surrogate variable for impotence in the Massachusetts Male Aging Study" 47 : 457-467, 1994

22 Marck RE, "Considerations on the use of platelet-rich plasma, specifically for burn treatment" 35 : 219-227, 2014

23 Gelbard M, "Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies" 190 : 199-207, 2013

24 Tang YQ, "Chimeric molecules facilitate the degradation of androgen receptors and repress the growth of LNCaP cells" 11 : 119-126, 2009

25 Xie X, "Biology of platelet-rich plasma and its clinical application in cartilage repair" 16 : 204-, 2014

26 Weiss RA, "Autologous cell therapy: will it replace dermal fillers" 21 : 299-304, 2013

27 Shirvan MK, "A novel method for iatrogenic vesicovaginal fistula treatment: autologous platelet rich plasma injection and platelet rich fibrin glue interposition" 189 : 2125-2129, 2013